Exin Therapeutics vs Yoneda Labs

Side-by-side comparison of AI visibility scores, market position, and capabilities

Yoneda Labs leads in AI visibility (36 vs 35)

Exin Therapeutics

EmergingHealthcare

General

SF AI neurotherapeutics discovery platform for epilepsy/autism/Parkinson's with multimodal neural AI; animal lab + proof-of-concept + 2 patents in 1.5 months; $25M Philippines lab investment competing with Recursion for AI-driven CNS gene therapy.

AI VisibilityBeta
Overall Score
D35
Category Rank
#1006 of 1167
AI Consensus
61%
Trend
stable
Per Platform
ChatGPT
35
Perplexity
43
Gemini
26

About

Exin Therapeutics is a San Francisco-based AI-powered neurotherapeutics drug discovery company — pioneering genetic therapies that target neural activity to treat epilepsy, autism spectrum disorder symptoms, Parkinson's disease, and other neurological conditions using a multimodal AI platform that predicts therapeutic candidate potential across multiple neural disorders simultaneously. Using neural activity recordings, behavioral assays, and transcriptomics data as inputs, Exin's AI models identify genetic intervention targets and predict therapeutic outcomes before entering animal studies — compressing the target identification timeline that traditional neuroscience drug discovery requires. The company established an animal research facility, obtained proof-of-concept results in mice, and filed two provisional patents within 1.5 months of San Francisco operations, and is investing approximately $25 million to build the Philippines' first neurotherapeutics laboratory.

Full profile

Yoneda Labs

EmergingHealthcare

General

AI chemical reaction optimization with 95% accuracy for drug discovery synthesis parameters; $4.5M from Khosla Ventures and YC competing to automate pharmaceutical process chemistry development.

AI VisibilityBeta
Overall Score
D36
Category Rank
#999 of 1167
AI Consensus
53%
Trend
stable
Per Platform
ChatGPT
44
Perplexity
32
Gemini
30

About

Yoneda Labs is a San Francisco-based AI company applying foundation models to automate chemical reaction optimization for drug discovery and pharmaceutical process development — providing chemists with AI systems that determine optimal reaction parameters (temperature, solvent, catalyst, concentration) for new chemical synthesis routes, achieving 95% accuracy in suggesting effective conditions for small-scale trials. Founded in 2023 and backed by Khosla Ventures, 468 Capital, 500 Global, and Y Combinator with $4.5 million raised including a $4 million seed round in April 2024, Yoneda Labs brings mathematical category theory foundations (the name references Yoneda's lemma in category theory) to chemistry AI.

Full profile

AI Visibility Head-to-Head

35
Overall Score
36
#1006
Category Rank
#999
61
AI Consensus
53
stable
Trend
stable
35
ChatGPT
44
43
Perplexity
32
26
Gemini
30
31
Claude
47
30
Grok
33

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.